FAD Treatment for Follicular Lymphoma
Author Information
Author(s): Yung L, Cunningham D, Hancock B, Smith P, Maclennan K, Linch D, McMillan A
Primary Institution: University College London
Hypothesis
Can fludarabine, adriamycin, and dexamethasone (FAD) be an effective first-line treatment for newly diagnosed advanced follicular lymphoma?
Conclusion
The combination of fludarabine, adriamycin, and dexamethasone can be administered with acceptable toxicity and results in a high response rate in patients with follicular lymphoma.
Supporting Evidence
- The overall response rate was 96%, with a complete response rate of 39%.
- Median follow-up was 50 months, with a 4-year overall survival rate of 72%.
- Only 3% of chemotherapy cycles resulted in grade 4 neutropenia.
Takeaway
This study tested a new combination of medicines to help people with a type of blood cancer, and it worked well for most of the patients.
Methodology
This was a single-arm phase II study evaluating the toxicity and efficacy of FAD in patients with newly diagnosed follicular lymphoma.
Potential Biases
Potential bias due to the single-arm design and lack of control group.
Limitations
The study had a small sample size and was not randomized.
Participant Demographics
Participants were 30 adults aged 29 to 76, with a median age of 55; 60% were male.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website